Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.745 | -10.4929577465 | 7.1 | 7.1 | 6.355 | 7541 | 7.02218353 | CS |
4 | -0.585 | -8.42939481268 | 6.94 | 7.59 | 6.355 | 16319 | 6.99503923 | CS |
12 | -7.395 | -53.7818181818 | 13.75 | 14.82 | 6.355 | 165037 | 11.87937234 | CS |
26 | -10.6275 | -62.5791255704 | 16.9825 | 17 | 6.355 | 160349 | 12.78887863 | CS |
52 | -9.0325 | -58.7002437043 | 15.3875 | 23.5 | 6.355 | 215125 | 15.60161427 | CS |
156 | -81.895 | -92.7988668555 | 88.25 | 92.5 | 6.355 | 190405 | 29.38584293 | CS |
260 | -387.895 | -98.3880786303 | 394.25 | 449.75 | 6.355 | 231379 | 75.6472265 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.